Economized large‐scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: The versatility of recombinant adeno‐associated vector (rAAV) as a gene delivery system is due to the vector's ability to transduce different cell types as well as dividing and non‐dividing cells. Large‐scale production of rAAV remains one of the major challenges for continued development of pre‐clinical and clinical studies, and for its potential commercialization. The baculovirus expression vectors (BEVS) and insect cells represent a potential method to produce rAAV economically at large scale. This technology uses three different BEV s (Bac‐Rep, Bac‐GFP, and Bac‐VP) each at a multiplicity of infection (MOI) of 3. We reported previously the production of rAAV at 40 L scale using a stirred‐tank bioreactor (STB). However, production in larger volumes is limited by the stability of the BEV s and amount of BEV s needed to achieve the target MOI of 3 per BEV. Here, the production parameters were optimized and the baculovirus stability was determined. Methods: The stability of the three types of baculovirus used to produce rAAV was determined for six expansion passages by protein expression analysis. To economize baculovirus, MOI and cell density at time of infection (TOI) were evaluated initially at small scale and then applied to the 10 L scale. Results: An MOI = 0.03 and TOI cell density of 1 × 10 6 cells/mL produced high titer rAAV without comprising yield. To confirm the scalability of the process, rAAV was produced in a 10 L STB using the optimized parameters obtaining a 10× increase in yield (∼1 × 10 14 rAAV DNAse‐resistant particles per liter). Conclusion: These findings contribute to the process development for large‐scale production of rAAV for gene therapy applications and its commercialization. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155 · cited 1×
“Recombinant adeno-associated vectors (rAAV) are emerging as a favorable gene transfer system for pre-clinical and clinical studies [1,2].”
Background
Cited by
Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.187 · Cited by 325
Felberbaum, R. S. (2015) · Biotechnology Journal · doi:10.1002/biot.201400438 · Cited by 264
Smith, R. H., Levy, J. R., & Kotin, R. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.128 · Cited by 261
Self-citationWright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
“For example, AAV vector production systems based on human cell lines [21–24] and insect cell lines [25–27] result in qualitative differences in the nature of residual host cell proteins and nucleic acids, with corresponding differences in the risk of potential immunotoxicity”
BackgroundManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Metadata
- Authors
- Negrete, A., Yang, L. C., Mendez, A. F., Levy, J. R., & Kotin, R. M.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2007-09-03
- Volume
- 9
- Issue
- 11
- Pages
- 938-948
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W1993891172
- Cited by
- 54
- References
- 2
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.